Shares of Quest Diagnostics Inc. (DGX) are rising over 7% in pre-market today, after the company announced the launch of consumer-initiated COVID-19 antibody test through QuestDirect.
The company noted that beginning today, individuals can purchase COVID-19 antibody testing for themselves online, without visiting a doctor's office, through the company's consumer-initiated testing business QuestDirect.
Each test request is reviewed and, if appropriate, an order for testing is issued by a licensed physician, the company said. Individuals have the opportunity to speak with a licensed physician about their results.
On April 21, Quest announced the launch of its COVID-19 antibody test service for healthcare providers to order on behalf of patients.
The stock has been trading between $73.02 and $118.58 in the past one year, and closed Monday's trade at $116.02, up $9.40 or 8.82%. DGX is currently trading at $124.95, up $8.93 or 7.70% in the pre-market trading session.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.